ABVD
Sign in to saveABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: Adriamycin (also known as doxorubicin/hydroxydaunorubicin, designated as H in CHOP) Bleomycin Vinblastine Dacarbazine (similar to procarbazine, designated as P in MOPP and in COPP)
~11 min read
Article
15 sectionsContents
- Medical uses
- Administration
- Side effects
- Acute side effects
- Delayed side effects
- Supportive care
- Antiemetics
- Growth factors
- History
- Development
- Research
- Fertility
- See also
- References
- External links
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: Adriamycin (also known as doxorubicin/hydroxydaunorubicin, designated as H in CHOP) Bleomycin Vinblastine Dacarbazine (similar to procarbazine, designated as P in MOPP and in COPP)
==Medical uses== As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. The other chemotherapy regimens that are widely used in this setting is the Stanford V and BEACOPP regimens.